Please ensure Javascript is enabled for purposes of website accessibility

Moderna's Teen COVID-19 Vaccine Trial Hits High Marks

By Cory Renauer - May 25, 2021 at 12:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company should submit its request for the FDA to authorize the use of its vaccine in those 12 and older in a couple of weeks.

On Tuesday, Moderna (MRNA -2.60%) reported highly successful results from a clinical trial of its COVID-19 vaccine in patients ages 12 to 17. Depending on how you look at the top-line data from the TeenCove study, mRNA-1273 was found to be between 93% and 100% effective at preventing new cases.

The TeenCOVE trial enrolled over 3,700 12- to 17-year-old participants. Going by the primary case definition of COVID-19, from a period starting 14 days after their second dose, none of the volunteers who received the vaccine have tested positive. And although new case numbers are plummeting across the country, four of the volunteers who received the placebo did test positive for COVID-19.

A smiling scientist

Image source: Getty Images.

Since teenagers are far less likely to present symptoms of COVID-19 when they're infected, investigators also used a more sensitive definition of COVID-19 positivity that requires just one symptom plus a positive nasal swab test. Based on those looser criteria, the vaccine was still 93% effective at preventing new cases.

The TeenCove trial results Moderna reported Tuesday stack up nicely against those reported in March by Pfizer (PFE 1.17%) and BioNTech (BNTX 0.21%)for their rival mRNA vaccine, Comirnaty. That said, comparisons between the two teen trials should be taken with a grain of salt. Pfizer and BioNTech ran their U.S.-based clinical trial in 12- to 15-year-olds at a time when far more Americans were contracting the virus.

Moderna plans to submit a completed data package from the TeenCOVE study to the FDA in early June. Given that its top-line results are roughly in line with those that earned Pfizer and BioNTech a green light for their vaccine to be administered to teens, we can reasonably expect a similar response from the regulator within a few days of its receiving Moderna's submission.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$146.10 (-2.60%) $-3.90
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.15 (1.17%) $0.57
BioNTech SE Stock Quote
BioNTech SE
BNTX
$147.92 (0.21%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.